



Ref: BHL/ STEX 5/ 2026-27

Date: May 07, 2026

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400 001  <b>Scrip Code: 539872</b>	National Stock Exchange of India Limited 5 <sup>th</sup> Floor, Exchange Plaza, Bandra Kurla Complex Bandra (East) Mumbai-400051  <b>Symbol: BAJAJHCARE</b>
---	--

Dear Sir/Madam,

**Sub: Intimation of Approval received for Listing of 20,79,409 equity shares of ₹5/- each allotted pursuant to conversion of warrants issued on preferential basis**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), as amended, we wish to inform you that Bajaj Healthcare Limited (“the Company”) has received listing approvals from National Stock Exchange of India Limited and BSE Limited (“Stock Exchanges”) for the listing of 20,79,409 equity shares of face value of ₹5/- each of the Company, allotted pursuant to the exercise of options for the conversion of convertible warrants into equity shares.

Please find enclosed herewith the listing approvals received from Stock Exchanges.

Kindly take the same on record.

Thanking You,

**For and Behalf of Board of Director of  
Bajaj Healthcare Limited**

**Monica Tanwar  
Company Secretary & Compliance Officer**

**BAJAJ HEALTHCARE LIMITED**

Registered Office: 602-606, Bhoomi Velocity Infotech Park, Plot No: B-39, B-39A, B-39A/1, Road No. 23, Wagle Ind. Estate, Thane (West), Thane - 400604  
Tel. : + 91 22 66177400/ 401; Fax : +91 22 66177458; E-mail : bajajhealth@bajajhealth.com  
CIN No. L99999MH1993PLC072892



Ref: NSE/LIST/54371

May 6, 2026

The Company Secretary  
Bajaj Healthcare Limited

Dear Sir/Madam,

**Sub: In - Principle approval for listing of 20,79,409 Equity shares of face value of Rs. 5/- each allotted pursuant to conversion of warrants issued on preferential basis.**

We are in receipt of your application for in-principle approval for listing of 20,79,409 Equity shares of face value of Rs. 5/- each allotted pursuant to conversion of warrants issued on preferential basis bearing distinctive numbers from 31583253 to 33662661.

We have perused the listing application and the related documents/details submitted by you for listing of the above shares.

We are pleased to grant the in-principle approval for listing of the above shares on the Exchange. The said shares would be listed and admitted to dealings on the Exchange on receipt of the confirmation from the depositories i.e. NSDL/CDSL for credit of beneficiaries' accounts.

Yours faithfully,  
For National Stock Exchange of India Limited

Pooja Pashte  
Manager

Cc:  
National Securities Depository Limited  
Central Depository Services Limited

P.S. Checklist of all the further issues is available on website of the exchange at the following URL:  
<https://www.nseindia.com/companies-listing/raising-capital-further-issues-main-sme-checklist>

*The National Stock Exchange of India (NSE) has announced the launch of NEAPS mobile application. The app can be downloaded from the App Store/ Play store with the name "NEAPS APP"*

This Document is Digitally Signed



Signer: POOJA RISHIKESH PASHTE  
Date: Wed, May 6, 2026 13:45:12 IST  
Location: NSE

LOD/PREF/RB/FIP/179/2026-27

May 06, 2026

To,  
The Company Secretary,  
**Bajaj Healthcare Ltd.**  
602-606, Bhoomi Velocity Infotech Park,  
Plot No. B-39 A/1, Road No. 23,  
Wagle Industrial Estate, Thane (West),  
Thane, Maharashtra, 400604

**Re: Listing of 20,79,409 equity shares of Rs. 5/- each issued at a premium of Rs. 333/- bearing distinctive numbers from 31583253 to 33662661 issued to Promoters and Non-Promoters on preferential basis pursuant to conversion of warrants.**

We acknowledge the receipt of your letter about the captioned matter, together with the enclosures and would advise that the Exchange is pleased to grant Listing approval to the listing application made by the company seeking permission for its aforesaid shares to be dealt in on the Exchange.

The Company should ensure compliance with the provisions of Regulation 167 of SEBI (ICDR) Regulations and as specified by SEBI from time to time.

Further, in case there is change exceeding two per cent of the total paid-up share capital of the company, the company shall file the shareholding pattern in XBRL mode as required under Regulations 31(1)(c) of SEBI LODR Regulations, 2015.

Please note that trading approval in the above-mentioned shares will be granted only after the company files with the Exchange:

- Listing approval from the National Stock Exchange of India Ltd. (if applicable) and
- Confirmation letters from NSDL/CDSL about crediting the above-mentioned shares to the respective beneficiary accounts/admitting the capital to the depository system. You are requested to file all such approvals together.
- Confirmation letters from NSDL/CDSL about lock-in of pre-preferential holding (if applicable)

In addition to above, the company should note that as per Schedule XIX of ICDR Regulations and as specified by SEBI vide SEBI circular no. SEBI/HO/CFD/PoD-2/P/CIR/2023/00094 dated June 21, 2023, "Listed entities shall make an application for trading approval to the stock exchange/s within seven working days from the date of grant of listing approval by the stock exchange/s" along with the documents specified by stock exchange/s from time to time. Any Non-compliance with the above requirement will attract fine as mentioned in SEBI circular no. SEBI/HO/CFD/PoD-2/P/CIR/2023/00094 dated June 21, 2023.

Yours faithfully,



**Marian D'souza**  
Assistant Vice President



**Hetika Chandni**  
Deputy Manager